BridgeBio (BBIO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Jun, 2026Opening remarks and agenda
Meeting commenced as an interactive webcast, following corporate bylaws and Delaware law.
Stockholders and guests were welcomed, and the agenda included reviewing and voting on proposals outlined in the proxy statement.
Voting procedures and rules of conduct were explained, with polls open during the meeting.
Board and executive committee updates
Directors and officers present were introduced, including the CEO, CFO, and other key executives.
Representatives from Deloitte (auditors), Goodwin Procter (outside counsel), and American Election Services (inspector of elections) attended.
Shareholder proposals
Five proposals were presented: election of three directors, advisory vote on executive compensation, advisory vote on frequency of compensation votes, ratification of Deloitte as auditor, and amendment to the stock option plan.
Board recommended approval of all proposals.
Latest events from BridgeBio
- Attruby launch drove $36.7M in new revenue, $116.6M total, and rapid adoption, but net loss widened.BBIO
Q1 20259 Jul 2026 - Oral infigratinib achieved best-in-class growth and proportionality with strong safety in achondroplasia.BBIO
Study result9 Jul 2026 - Q3 revenue surged on new launches; pipeline and cash position support 2026 NDA filings.BBIO
Q3 20258 Jul 2026 - Infigratinib delivers sustained growth and proportionality gains in achondroplasia with strong safety.BBIO
Study Result8 Jul 2026 - ATTR-CM launch outperformed, with three late-stage pipeline catalysts expected within 18 months.BBIO
Bank of America 2025 Healthcare Conference8 Jul 2026 - Accelerating sales and robust clinical data drive growth and pipeline momentum in rare diseases.BBIO
UBS Global Healthcare Conference 20258 Jul 2026 - Oral infigratinib significantly improved growth and body proportions in children with achondroplasia.BBIO
Conference presentation29 Jun 2026 - Attruby’s rapid growth and differentiated data anchor a pipeline poised for multiple rare disease launches.BBIO
Jefferies Global Healthcare Conference 20264 Jun 2026 - Late-stage pipeline and strong cash position drive multiple launches in rare genetic diseases.BBIO
Corporate presentation4 Jun 2026